SEC For	m 4 FORM	Л) STA	TES SI	FCURITIE	S AN	DF	ХСНА	NG		оммі	SSION					
						TES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549									OMB APPROVAL			
Section 16. Form 4 or Form 5 obligations may continue. See					AT OF CHANGES IN BENEFICIAL OWNERSHIP d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940								SHIP	Estim	OMB Number: 3235-0287 Estimated average burden hours per response: 0.5			
1. Name and Address of Reporting Person* BERSANI PIETRO					2. Issuer Name and Ticker or Trading Symbol <u>Kiromic Biopharma, Inc.</u> [KRBP]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) C/O KIROMIC BIOPHARMA INC.					3. Date of Earliest Transaction (Month/Day/Year) 10/05/2023							2	X Officer (give title Other (specify below) CEO					
7707 FANNIN, SUITE 140						4. If Amendment, Date of Original Filed (Month/Day/Year)								ndividual or Joint/Group Filing (Check Applicable e)				
(Street) HOUST	ON TZ	X		Fo									filed by One Reporting Person filed by More than One Reporting on					
(City)	(S	tate)	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.															
		Tab	le I - Nor	-Deriva	ative Se	curities Aco	quired,	Disp	osed o	of, o	r Bene	eficiall	y Owned					
Date				2. Transa Date (Month/D	ay/Year)	2A. Deemed Execution Date, if any (Month/Day/Year	3. Transaction Code (Instr. 8)		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)						Form (D) o	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
							Code	v	Amount		(A) or (D)	Price	Transact	Transaction(s) Instr. 3 and 4)			(1130.4)	
		1				urities Acqu s, warrants,							Owned					
1. Title of Derivative Security (Instr. 3)	ative Conversion Date Execution Date if any			Date, Ti C	ransaction ode (Instr.	of	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		ecurity	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported	e s lly J	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	

						3, 4 and 5)							(Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Restricted Stock Units	(1)	10/05/2023		A		65,600		(1)	(1)	Common Stock	65,600	\$ <mark>0</mark>	65,600	D

Explanation of Responses:

1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. 49,200 of the RSUs vest upon date of grant, 5,467 vest on October 31, 2023, 5,467 vest on November 30, 2023 and 5,466 vest on December 31, 2023 provided that the Reporting Person remains in continuous service on each vesting date.

<u>/s/ Pietro Bersani</u>

** Signature of Reporting Person Date

10/06/2023

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.